Home > Boards > US Listed > Biotechs > Inovio Pharmaceuticals, Inc. (INO)

Genetic Testing for Cancer

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
hlegweakreturns Member Profile
Followed By 1
Posts 447
Boards Moderated 0
Alias Born 07/31/13
160x600 placeholder
Inovio Pharmaceuticals to Participate in Upcoming Investor Conferences "GlobeNewswire Inc." - 2/2/2016 8:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 1/28/2016 4:10:44 PM
Inovio Pharmaceuticals and GeneOne Life Science Initiate Patient Recruitment for MERS Vaccine Trial "GlobeNewswire Inc." - 1/28/2016 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/26/2016 4:40:59 PM
GeneOne Life Science and Inovio Pharmaceuticals to Collaborate on Zika Virus Vaccine Development "GlobeNewswire Inc." - 1/22/2016 5:00:00 AM
Inovio Pharmaceuticals Awarded Grant to Advance Needle-Free Vaccine Delivery Device "GlobeNewswire Inc." - 1/19/2016 8:00:00 AM
Inovio Pharmaceuticals to Present at Biotech Showcase "GlobeNewswire Inc." - 1/5/2016 8:00:00 AM
Inovio Pharmaceuticals Adds Dr. Prakash Bhuyan to VGX-3100 Leadership Team for HPV-Related Dysplasia "GlobeNewswire Inc." - 1/4/2016 8:00:00 AM
The 3 Most Important Drugs in Inovio Pharmaceuticals' Pipeline "The Motley Fool" - 12/4/2015 8:38:03 AM
Inovio Pharmaceuticals to Present at Piper Jaffray Healthcare Conference "GlobeNewswire Inc." - 11/23/2015 8:00:00 AM
GeneOne Life Science and Inovio Pharmaceuticals’ MERS Vaccine Approved for First-in-Human Study "GlobeNewswire Inc." - 11/19/2015 9:00:00 AM
Inovio Pharmaceuticals Produces a Rare Quarterly Profit, but Don't Get Too Excited Just Yet "The Motley Fool" - 11/12/2015 2:32:03 PM
GeneOne Life Science and the Walter Reed Army Institute of Research Partner to Develop MERS Vaccine "GlobeNewswire Inc." - 11/10/2015 3:17:28 PM
Here's Why Inovio Pharmaceuticals Had the Cure for Investors' Ills in October "The Motley Fool" - 11/10/2015 8:02:02 AM
Inovio Pharmaceuticals Reports 2015 Third Quarter Results "GlobeNewswire Inc." - 11/9/2015 7:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/9/2015 6:26:20 AM
Inovio’s INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer "GlobeNewswire Inc." - 11/5/2015 8:00:00 AM
Is Inovio Pharmaceuticals a Late Bloomer? "The Motley Fool" - 10/30/2015 3:06:02 PM
Inovio Pharmaceuticals to Host Third Quarter 2015 Financial Results Conference Call November 9, 2015 "GlobeNewswire Inc." - 10/26/2015 8:00:00 AM
Inovio and Partner Advance MERS Vaccine "GlobeNewswire Inc." - 10/19/2015 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/30/2015 2:40:31 PM
Inovio to Participate in Upcoming Investor Conferences "GlobeNewswire Inc." - 9/30/2015 8:00:00 AM
Inovio's Chief Operating Officer Selected by PharmaVoice as One of the Most Inspirational Leaders in the Global Industry "GlobeNewswire Inc." - 9/21/2015 8:46:16 PM
Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine "GlobeNewswire Inc." - 9/21/2015 8:46:02 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/17/2015 11:24:45 AM
hlegweakreturns   Friday, 10/18/13 06:04:49 AM
Re: None
Post # of 13252 
Genetic Testing for Cancer
Is evolving very quickly and many folks are getting into the business. And there is more than one in New Jersey. Roche is entering this market, and they are not alone. Yesterday Bloomberg had an article on Quest entering the Breast-Cancer Test Market that is currently dominated by Myriad. I don't think Roche has any interest in Quest, but they obviously are looking for expanding their genetic diagnostic capability going forward, as evidenced by the PACB deal, and another agreement with a smaller, and interesting player in this market. So here is the article if you have any interest in tangential developments:

"Quest Diagnostics Inc. (DGX), the biggest U.S. operator of medical labs, began yesterday to sell a test for two breast cancer genes, providing competition for Myriad Genetics Inc. and potentially helping to reduce costs for women fearful they are at risk of the disease.Quest will sell the most comprehensive version of its test for the BRCA1 and BRCA2 genes for $2,500, said Richard Bender, a consultant for the Madison, New Jersey-based company. The price compares with almost $3,400 that Medicare pays for the most comprehensive version of a test from Myriad.

Myriad held a U.S. monopoly over the BRCA tests until June, when the U.S. Supreme Court invalidated parts of its gene patents. Immediately afterward, Ambry Genetics Corp. and another closely held company said they were entering the BRCA market. Quest is the largest competitor to move into the field. Quest’s test “will certainly be comparable to if not better than the data provided by Myriad” in its ability to identify a harmful mutation, Bender said by telephone.
Quest’s incursion into the BRCA testing market sets up a potential legal battle with Myriad, which has various remaining patents on its tests. “We feel we offer a test that is the gold standard in quality,” Ronald Rogers, a Myriad spokesman, said in a phone interview."

Quest’s test “does not violate any valid BRCA patent that Myriad Genetics may assert,” Wendy Bost, a Quest spokeswoman, said in an e-mail.
Quest said in an Oct. 10 complaint filed in federal court in Santa Ana, California, that it believes Myriad will bring a patent-infringement lawsuit if it starts selling its BRCA test products.
Myriad hasn’t yet been served with Quest’s complaint, said Rogers. “Once we receive that, we will read through it and weigh our options,” he said.
The case is Quest Diagnostics Inc. v. Myriad Genetics Inc. (MYGN), 13-cv-01587, U.S. District Court, Central District of California (Santa Ana).

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist